
While initially characterised in paediatric patients, PFIC can manifest later in life after a specific trigger or patients may remain undiagnosed into adulthood¹⁻³

PFIC can be difficult to diagnose in adults due to variable genotypes and phenotypes that often differ from patients with paediatric-onset PFIC^{4–6}

Explore the algorithm below to learn more about the patient presentations that may benefit from reassessment for PFIC



Adapted from Dröge C et al, 2023;7 Alkhouri N, 2023;3 European Association for the Study of the Liver (EASL). EASL Clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009:51:237–267.8

AMA, antimitochondrial antibodies; ANA, antinuclear antibodies; DILI, drug-induced liver injury; GGT, gamma-glutamyl transferase; gp210; glycoprotein 210; HCC, hepatocellular carcinoma; ICP, idiopathic cholesitasis; MASLD, metabolic dysfunction-associated steatohepatitis; MRCP, magnetic resonance cholangiopancreatography; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; sp100, speckled protein 100; SSC, secondary sclerosing cholangitis.


1. Vitale G et al. Cancers 2022;14:3421; 2. Althwanay A et al. Am J Gastroenterol 2022;117:p e2058; 3. Alkhouri N. Presented at AASLD 2023, Boston, US; 10–14 November; 4. Vitale G et al. J Gastroenterol 2018;53:945–958; 5. Nayagam JS et al. Hepatol Commun 2022;6:2654–2664; 6. Schatz SB et al. Hepatol Comms 2018;2:504–514; 7. Dröge C et al. Explor Dig Dis 2023;2:34–43; 8. EASL. J Hepatol 2009;51:237–267; 9. Vitale G et al. Dig Liver Dis 2019;51:922–933; 10. Ganne-Carrie N et al. J Hepatol 2003;8:693–697; 11. Mirza N et al. J Child Sci 2020;10:e134–e136; 12. Boehlig A et al. Biomedicines 2022;10:451.

August 2024 | DRSC-UK-000577 | This material has been commissioned by Ipsen and is intended for UK healthcare professionals only.

Certain patient presentations of progressive cholestatic liver disease may signal the need for further assessment⁷







CHOLESTATIC PRURITUS FOLLOWING RECENT LIVER ISSUE

Secondary cholestasis triggered by a liver issue can be a sign of PFIC.¹


Consider reassessing your patient for PFIC if they present with cholestatic pruritus following a

• Hormone-induced cholestasis (cholestasis triggered by birth control, menopause, etc.)^{4,5}

1. Alkhouri N. Presented at AASLD 2023, Boston, US; 10–14 November; 2. Hardikar W et al. World J Gastroenterol 2009;15:1126–1129; 3. Vitale G et al. Dig Liv Dis 2019;51:922–933;








HISTORY OF COMPLICATED GALLSTONES, LPAC OR FAMILY HISTORY OF GALLSTONES


Gallstones are a known complication of PFIC¹ and low phospholipid-associated cholelithiasis (LPAC) is linked to mutations in the ABCB4 gene,² which is one of the genes most associated

• Strong family history of gallstones and incident at a young age

1. Jankowska I and Socha P. Clin Res Hepatol Gastroenterol 2012;36:271–274; 2. Vitale G et al. Cancers 2022;14:3421; 3. Nayagam JS et al. Hepatol Commun 2022;6:2654–2664;








FAMILY HISTORY OF LIVER DISEASE OR LIVER ISSUE


PFIC is a hereditary condition caused by mutations in at least 12 genes, including ATP8B1,

As these genes have also been implicated in other liver diseases, you might consider reassessing your patient for PFIC if they have a family history of:










INSUFFICIENT RESPONSE TO CHOLESTATIC/CHOLANGIOPATHIC LIVER DISEASE TREATMENT DESPITE COMPLIANCE

For patients diagnosed with a cholestatic/cholangiopathic liver disease other than PFIC, poor

Consider reassessing for PFIC in your patients with insufficient response to therapy for a different cholestatic/cholangiopathic liver disease despite good compliance.








CHOLESTASIS WITH UNUSUAL PRESENTATION

If your patient is receiving care for another liver disease but has unusual symptoms, it could

• Lean MASH with pruritus and without metabolic syndrome^{7,8}

AMA, antimitochondrial antibody; MASLD, metabolic dysfunction-associated steatotic liver disease; MASH, metabolic dysfunction-associated steatohepatitis; PBC, primary biliary cholangitis;

2017;10.12890/2016_000537; 4. Chascsa DM and Lindor KD. Clin Liver Dis 2018;22:589-601; 5. Zen Y et al. In: Burt AD et al, eds. MacSween's Pathology of the Liver. 7th ed. 2018:515–593; 6. Nalbantoglu I and Jain D. Semin Diagn Pathol 2019; 10.1053/j.semdp.2019.07.003; 7. Boehlig A et al. Biomedicines 2022;10:451; 8. Nayagam JS et al. Hepatol Commun 2022;6:2654–2664.






While initially characterised in paediatric patients, PFIC can manifest **later in life** after a specific trigger or patients may remain undiagnosed into adulthood^{1–3}

PFIC can be difficult to diagnose in adults due to variable genotypes and phenotypes that often differ from patients with paediatric-onset PFIC^{4–6}

Explore the algorithm below to learn more about the patient presentations that may benefit from reassessment for PFIC



Adapted from Dröge C et al, 2023;⁷ Alkhouri N, 2023;³ European Association for the Study of the Liver (EASL). EASL Clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009:51:237–267.⁸

AMA, antimitochondrial antibodies; ANA, antinuclear antibodies; DILI, drug-induced liver injury; GGT, gamma-glutamyl transferase; gp210; glycoprotein 210; HCC, hepatocellular carcinoma; ICP, idiopathic cholesitasis; MASLD, metabolic dysfunction-associated cholelithiasis; MASLD, metabolic dysfunction-associated steat steat steat steat steat cholesitasis; maschare steat cholesitas; maschare steat stea

Vitale G et al. Cancers 2022;14:3421;
Althwanay A et al. Am J Gastroenterol 2022;117:p e2058;
Alkhouri N. Presented at AASLD 2023, Boston, US; 10–14 November;
Vitale G et al. J Gastroenterol 2018;53:945–958;
Alkhouri N. Presented at AASLD 2023, Boston, US; 10–14 November;
Vitale G et al. J Gastroenterol 2018;53:945–958;
Alkhouri N. Presented at AASLD 2023, Boston, US; 10–14 November;
Vitale G et al. J Gastroenterol 2018;53:945–958;
Alkhouri N. Presented at AASLD 2023, Boston, US; 10–14 November;
Vitale G et al. J Gastroenterol 2018;53:945–958;
Alkhouri N. Presented at AASLD 2023;8:693–697;
Vitale G et al. J Gastroenterol 2018;53:945–958;
Vitale G et al. J Child Sci 2020;10:e134–e136;
Boehlig A et al. J Child Sci 2020;10:e134–e136;

August 2024 | DRSC-UK-000577 | This material has been commissioned by Ipsen and is intended for UK healthcare professionals only.

Certain patient presentations of progressive cholestatic liver disease may signal the need for further assessment⁷

COULD IT BE PFIC?

MAKING A DIAGNOSIS

C CHOLESTASIS	low to learn tests for C
ible for PFIC have been identified in a number of patients with	e sts ds
ent if signs of cholestasis manifest without an apparent or le presence of pruritus. ^{1,2}	analysis ;B4, TJP2,)5B
	ore?
	FIC , visit: y/211600
ol 2018;53:305–311.	onset PFI tol Commu 4








nun

hepatitis;



BIOCHEMICAL TESTS

A range of biochemical abnormalities may indicate PFIC, including elevated serum bile acid levels, elevated bilirubin levels and abnormal transaminase levels.^{1,2}

PFIC type 1	PFIC type 2	PFIC type 3
$\uparrow\uparrow$	$\uparrow\uparrow\uparrow$	1
-	-	1
1	1	1
\uparrow	1	\uparrow
1	1	1

This table only includes PFIC types 1, 2 and 3. Please see www.omim.org/entry/211600 for more information on other PFIC types.

If PFIC is suspected, assessment of these measures can help confirm a diagnosis²





GENETIC ANALYSIS



 \bigcirc

So far, variations in at least 12 genes have been associated with PFIC.¹ These include:^{1,2}

- ATP8B1, encoding FIC1 PFIC type 1
- ABCB11, encoding BSEP PFIC type 2
- *ABCB4*, encoding MDR3 PFIC type 3
- *TJP2*, encoding TJP2 PFIC type 4
- *NR1H4*, encoding FXR PFIC type 5
- *MYO5B*, encoding MYO5B PFIC type 10

Genetic testing can be useful to reinforce a suspected diagnosis of PFIC.³ A lower threshold for genetic testing could lead to earlier diagnosis of PFIC, allow screening for family members,⁴ and be key to facilitating individualised treatment.³

However, genetic testing for PFIC has certain limitations, including:

- Difficulty in predicting pathogenicity of new variants⁶
- Inconsistency in genotype-phenotype relationships^{6,7}
- Mutations may reside in as-yet-undiscovered causative genes or regions of genes that are not evaluated in genetic assays, meaning testing can be inconclusive^{2,7,8}

Genetic testing is not essential for a positive diagnosis of PFIC and should not delay treatment initiation. In the absence of genetic confirmation, information obtained by probing the patient's family history may support a clinical diagnosis of PFIC.^{6,9,10}

PFIC, progressive familial intrahepatic cholestasis. 1. OMIM. PS211600. Available at:

https://www.omim.org/clinicalSynopsis/table?mimNumber=601847,619484,619658,602347,615878,619662,617049,619849,619874,620010,619868,211600&from=PS211600. Accessed August 2024; 2. Bull L and Thompson RJ. Clin Liver Dis 2018;22:657–669; 3. Vitale G et al. J Gastroenterol 2018;53:945–958; 4. Althwanay A et al. Am J Gastroenterol 2022;117:p e2058; 5. Nayagam JS et al. Hepatol Commun 2022;6:2654–2664; 6. McKiernan P et al. JHEP Reports 2024;6:100949; 7. Davit-Spraul A et al. Hepatology 2010;51:1645-1655; 8. Bakir A et al. Ann Hum Genet 2021;10.1111/ahg.12456; 9. Vitale G et al. Dig Liv Dis 2019;51:922–933; 10. Mirza N et al. J Child Sci 2020;10:e134–e136.

